Drug
Docetaxel
Docetaxel: highest development phase Phase 2, developed by Merck, Sanofi. 3 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Merck, Sanofi
Trials
| Drug | Phase | Indication |
|---|---|---|
| Docetaxel NCT00343239 | Phase 2 | Stomach Neoplasms |
| docetaxel NCT00225420 | Phase 1/2 | Prostate Cancer |
| Docetaxel NCT06863272 | Phase 1/2 | Castration-Resistant Prostatic Cancer |
Latest
No recent events.
Follow Docetaxel on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.